CONMED Corporation
NYSE:CNMDMedical - Devices
+$0.24 today
- Market cap
- $1.43B
- Beta
- 0.92
- P/E (TTM)
- 18.0
- EPS (TTM)
- $1.79
- Dividend yield
- 1.24%
Volume 0.36M
Average 0.45M
CNMD Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
CONMED CorporationNYSE: CNMD
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures dips below year-ago levels
Q1 FY2026 capital expenditures of $2.89M (cash outflow) fell 23.5% year over year, behind the +27.6% change in trailing-twelve-month capital expenditures. Sequentially, it fell 43.4% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.
Context
- Capital expenditures amounted to 1.4% of revenue in FY2025, up 0.4 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -23.5% toward the trailing-twelve-month pace of +27.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (19.81M) USD
- Year-over-year change
- -51.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.81M) | -51.4% |
| FY2024 | 2024-12-31 | (13.08M) | +31.3% |
| FY2023 | 2023-12-31 | (19.03M) | +12.6% |
| FY2022 | 2022-12-31 | (21.79M) | -46.5% |
| FY2021 | 2021-12-31 | (14.87M) | — |
Capital Expenditures vs competitors
How CNMD compares with its peers on the latest reported figures
- CNMD's LTM Mar 2026 capital expenditures of $18.92M is the 6th largest of the 11 companies compared; the peer median is $15.67M.
- Its year-over-year change of +27.6% is the 6th highest of 11, against a peer median of +11.9%.
- Capital expenditures amounts to 1.4% of revenue for CNMD, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $408.02M | +30.0% | -0.8% | 14.3% | |
| LTM Aug 2026 | $35.5M | -60.6% | -7.9% | 4.0% | |
| LTM Jan 2026 | $33.27M | +68.5% | — | 39.7% | |
| LTM Sep 2026 | $30.08M | -11.2% | -8.6% | 4.8% | |
| LTM Mar 2026 | $21.19M | -49.2% | +7.7% | 3.1% | |
| LTM Mar 2026 | $18.92M | +27.6% | -3.1% | 1.4% | |
| LTM Jun 2026 | $10.16M | -6.2% | -2.1% | 1.6% | |
| LTM Sep 2026 | $8.27M | +35.5% | -41.9% | 3.1% | |
| LTM Mar 2026 | $2.84M | +101.9% | — | 5.9% | |
| LTM Mar 2026 | $1.12M | +73.4% | -14.9% | 0.3% | |
| LTM Mar 2026 | $473K | -88.2% | -53.7% | 0.7% | |
| Peer median (excluding CNMD) | $15.67M | +11.9% | -8.3% | 3.6% | |
Competitors are the stored peer set for CNMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 62.54M | (80.58M) | 64.46M | 132.42M | 47.06M |
| Depreciation & Amortization | 70.74M | 69.52M | 51.4M | 51.31M | 74.28M |
| Deferred Income Tax | 3.01M | (6.04M) | 700K | 12.2M | 3.52M |
| Stock-Based Compensation | 16.34M | 21.73M | 24.26M | 25.56M | 28.32M |
| Change in Working Capital | (55.7M) | (90.7M) | (39.58M) | (39.72M) | (11.45M) |
| Accounts Receivables | (9.16M) | (5.2M) | (47.07M) | (1.62M) | (2.36M) |
| Inventory | (37.81M) | (78.56M) | 14.07M | (31.63M) | (6.73M) |
| Accounts Payables | 4.89M | 13.3M | 14.85M | 14.71M | (9.75M) |
| Other Working Capital | (13.62M) | (20.23M) | (21.43M) | (21.19M) | 7.39M |
| Other Non-Cash Items | 14.84M | 119.44M | 24.11M | (14.8M) | 28.96M |
| Operating Cash Flow | 111.77M | 33.37M | 125.35M | 166.97M | 170.69M |
| Capital Expenditures | (14.87M) | (21.79M) | (19.03M) | (13.08M) | (19.81M) |
| Acquisitions (Net) | 0 | (227.74M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1M) | 0 | (1.15M) |
| Investing Cash Flow | (14.87M) | (249.53M) | (20.03M) | (13.08M) | (20.96M) |
| Debt Repayment | (81.24M) | 362.02M | (88M) | (72M) | (74.59M) |
| Common Stock Issued | 0 | 72M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | (72M) | 0 | 0 | 0 |
| Dividends Paid | (23.26M) | (23.96M) | (24.5M) | (24.65M) | (24.75M) |
| Other Financing Activities | 2.95M | (113.06M) | 2.07M | (54.35M) | (36.49M) |
| Financing Cash Flow | (101.55M) | 225M | (110.43M) | (151M) | (135.82M) |
| Effect of Forex Changes | (1.87M) | (741K) | 470K | (2.72M) | 2.45M |
| Net Change in Cash | (6.51M) | 8.1M | (4.65M) | 163K | 16.36M |
| Free Cash Flow | 96.9M | 11.58M | 106.32M | 153.88M | 150.88M |
CONMED Corporation
NYSE:CNMD
Intrinsic Alpha fair value
Locked
Current Price
$48.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.